pharmaceuticals
pharmaceuticals Articles
Rigel Pharmaceuticals shares slid on Thursday after the company announced results from its late-stage clinical trial.
Published:
Last Updated:
Americans generally would like to spend less money on health care. One way that this can be and will be accomplished is through the continued use and expanded use of generic drugs.
Published:
Last Updated:
Nektar Therapeutics plans to price 13 million shares at $13.50 for a secondary offering valued up to almost $202 million.
Published:
Last Updated:
Depomed has settled with Starboard Value in a move that will bring this activist investor fight to a close. At least for now.
Published:
Last Updated:
Johnson & Johnson released a better-than-expected third-quarter report before the markets opened on Tuesday.
Published:
Last Updated:
A new research report from Jefferies notes that when price momentum has been as bad as it has been recently, it tends to rebound in a big way.
Published:
Last Updated:
ContraVir Pharmaceuticals watched its shares make a handy gain in Monday’s session after the company announced a positive development in its mid-stage hepatitis B trial.
Published:
Last Updated:
Myovant Sciences expects to price its 13 million shares in the range of $12 to $15 per share for an initial public offering valued up to more than $224 million.
Published:
Last Updated:
Johnson & Johnson is expected to release its most recent earnings report before the markets open on Tuesday.
Published:
Last Updated:
Ra Pharmaceuticals expects to price its almost 6 million shares in the range of $12 to $14 per share for an initial public offering valued up to more than $93 million.
Published:
Last Updated:
ContraVir Pharmaceuticals Inc. (NASDAQ: CTRV) is watching its shares climb on Thursday after the company reported positive interim data from its ongoing Hepatitis B (HBV) mid-stage trial....
Published:
Last Updated:
Ra Pharmaceuticals filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No pricing details were given in the filing, but in the previous...
Published:
Last Updated:
Myovant Sciences has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
Published:
Last Updated:
Ocular Therapeutix and Regeneron are attempting to develop a sustained release formulation of aflibercept that is suitable for advancement into clinical development.
Published:
Last Updated: